Trial reportFrontiers in immunology2025
Efficacy and safety of combined loratadine and mometasone furoate therapy in allergic rhinitis patients.
Trial report in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Investigation of the Anti-Pathogens (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study seeks to assess the effectiveness and safety of a combination treatment involving loratadine and mometasone furoate for patients suffering from allergic rhinitis (AR). Additionally, it explores the risk factors contributing to treatment failure, providing a theoretical basis for identifying safer and more effective AR treatments. Methods: A prospective study was carried out between January 1, 2021, and April 1, 2023, involving 116 patients with allergic rhinitis (AR) who were treated at our outpatient clinic. Participants were randomly divided into two groups: the control group (n=58), which received loratadine alone, and the study group (n=58), which received a combination of loratadine and mometasone furoate. Outcome measures included nasal symptom scores and serological markers, assessed before and after the treatment period. The effectiveness of the treatment was assessed using nasal symptom scores. Results: Post-treatment assessments showed that both nasal symptom scores and serological markers were significantly lower in the study group compared to the control group (P<0.05). Additionally, the overall response rate was markedly higher in the study group (P<0.05). There were no significant differences in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion: The combination of loratadine and mometasone furoate effectively alleviates clinical symptoms in patients with allergic rhinitis while demonstrating a favorable safety profile, making it a promising option for clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.